Foote K D, Brocklebank J T, Meadow S R
Lancet. 1985 Oct 26;2(8461):917-9. doi: 10.1016/s0140-6736(85)90851-7.
The heights of 80 patients with steroid-responsive nephrotic syndrome (SRNS) were measured 5-24 years after diagnosis. During childhood most patients had received repeated courses of high-dose corticosteroids and prolonged maintenance therapy. Although at the time of taking corticosteroids growth was suppressed, those who had completed growth had a mean height standard deviation score (SDS) of -0.22, equivalent to a height on the 40th centile. Total corticosteroid dose prescribed was correlated only weakly with height SDS; there was no correlation between total dose and height when the post-pubertal patients were studied separately, indicating that their ultimate height attainment was not affected significantly.
对80例类固醇反应性肾病综合征（SRNS）患者在诊断后5至24年进行了身高测量。在儿童时期，大多数患者接受了多次大剂量皮质类固醇疗程和长期维持治疗。尽管在服用皮质类固醇期间生长受到抑制，但那些已完成生长的患者的平均身高标准差评分（SDS）为-0.22，相当于第40百分位的身高。所开的皮质类固醇总剂量与身高SDS仅呈弱相关；当分别研究青春期后患者时，总剂量与身高之间没有相关性，这表明他们的最终身高并未受到显著影响。
